T. Maddala

发表

2131 DEVELOPMENT AND VALIDATION OF THE BIOPSY-BASED GENOMIC PROSTATE SCORE (GPS) AS A PREDICTOR OF HIGH GRADE OR EXTRACAPSULAR PROSTATE CANCER TO IMPROVE PATIENT SELECTION FOR ACTIVE SURVEILLANCE

M. Cooperberg, P. Carroll, M. Kattan, 2013 .

Measuring what people value: a comparison of "attitude" and "preference" surveys.

Kathryn A Phillips, F Reed Johnson, F. Johnson, 2002, Health services research.

Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry

S. Shak, A. Gown, L. Habel, 2009, Breast Cancer Research.

HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death

S. Shak, A. Gown, L. Habel, 2009, Breast Cancer Research.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.

F. Couch, E. Hubbell, Anton Valouev, 2018 .

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer.

C. Magi-Galluzzi, E. Klein, W. Novotny, 2012 .

Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis

P. Febbo, M. Dall’Era, T. Maddala, 2015, Urology practice.

Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.

S. Plevritis, E. Hubbell, Anton Valouev, 2018, Journal of Clinical Oncology.

Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2008 .

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: Implications for interpretation of liquid biopsy tests.

M. Berger, E. Hubbell, J. Reis-Filho, 2017 .

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.

Margarita Lopatin, Serge Koscielny, Ming Zhou, 2015, The Lancet. Oncology.

An experiment on simplifying conjoint analysis designs for measuring preferences.

Kathryn A Phillips, K. Phillips, T. Maddala, 2003, Health economics.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

P. Febbo, M. Cooperberg, P. Carroll, 2014, European urology.

Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer.

M. Berger, S. Gnerre, J. Reis-Filho, 2017 .

Detection and characterization of lung cancer using cell-free DNA fragmentomes

Adith S. Arun, H. Nielsen, R. Scharpf, 2021, Nature Communications.

Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.

E. Fung, Minetta C. Liu, A. Aravanis, 2019, Journal of Clinical Oncology.

Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.

R. Tibshirani, T. Yeatman, E. Hubbell, 2018 .

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

P. Febbo, M. Cooperberg, P. Carroll, 2016, Urology.

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

David R. Jones, M. Ladanyi, E. Hubbell, 2019, Nature Medicine.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Nan Zhang, Amina Ali, P. Febbo, 2015, European urology.

Title Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate

P. Febbo, M. Cooperberg, P. Carroll, 2016 .

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

L. Goldstein, A. Gown, S. Shak, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate Cancer A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low-and Intermediate-risk Prostate Cancer

P. Febbo, S. Srivastava, I. Sesterhenn, 2015 .

Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing.

Kathryn A Phillips, F Reed Johnson, F. Johnson, 2002, Health services research.

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

S. Shak, B. Uziely, J. Zidan, 2017, npj Breast Cancer.

Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect

P. Febbo, C. Magi-Galluzzi, E. Klein, 2016, Oncotarget.

HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197

R. Gray, G. Sledge, S. Shak, 2008 .

Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197

R. Gray, S. Shak, S. Badve, 2007 .

Reply to J.M. Guinebretiere and L. Arnould et al

E. Perez, S. Martino, G. Sledge, 2009 .

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

M. Ladanyi, E. Hubbell, C. Rudin, 2019, Nature Medicine.

Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC).

Ming Zhou, B. Rini, W. Novotny, 2010 .

BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection

H. Scher, C. Clarke, P. Kuhn, 2022, Clinical and translational science.

Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: The circulating cell-free genome atlas (CCGA) study.

E. Hubbell, A. Aravanis, J. Beausang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

S. Shak, B. Uziely, J. Zidan, 2017, npj Breast Cancer.

Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy.

C. Magi-Galluzzi, E. Klein, W. Novotny, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.

T. Yeatman, E. Hubbell, Anton Valouev, 2018 .

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

D. Berry, S. Cummings, E. Fung, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.